tiprankstipranks
pc:acc50

Accro Bioscience

Suzhou, Jiangsu, CN
https://www.accropeutics.com/
A clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulatory cell death for immune-mediated diseases. The company is advancing a multi-asset pipeline including AC-101, a RIPK2 inhibitor in development for ulcerative colitis, aiming to deliver targeted therapies for inflammatory and autoimmune conditions.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation―
Estimated Valuation―
Total Amount Raised$50M
Total Amount Raised$50M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$50M
Latest Funding Amount$50M
Latest Funding RoundSeries C
Latest Funding RoundSeries C
Post-Money Valuation―
Post-Money Valuation―

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
May 19, 2026
Series C
$50.00M
―

Investors

Investor Name
Funding Round

Similar Companies

A snapshot of private companies similar to Accro Bioscience, helping you discover and navigate related company profiles.

Related News and Analysis